NKG2A is an inhibitory receptor protein found on the surface of CD8 + T cells and natural killer (NK) cells ... In the context of MM therapy, ICIs primarily block the binding of inhibitory immune ...

Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...

Creating cancer therapies based around natural killer cells could offer similar levels of efficacy to CAR-T therapies, but at around one hundredth of the cost. Researchers at MD Anderson Cancer ...

There is substantial interest in the development of therapeutic approaches to treat IgG-mediated autoimmune diseases that target B cells and plasma ... the neonatal Fc receptor (FcRn), which ...

New fuel cell module will reduce ... for Fleets" presentation block Honda is concurrently beginning discussions with potential customers for its next generation FC module, set to enter production ...

Researchers have discovered how to block cells dying, in a finding that could lead to new treatments for neurodegenerative conditions like Parkinson’s and Alzheimer’s. The team at WEHI, including ...

A coalition of states sued the Trump administration Monday to block sweeping cuts to the U.S. Department of Health and Human Services, arguing they are unconstitutional and endanger Americans.

State Senate budget writers reversed $151 million in cuts made by the House as they began assembling their own two-year spending plan on Friday. The House cuts had been made to Medicaid providers ...

The partnership aims to commercialise cell therapies for solid tumour treatments. Credit: Freedomz / Shutterstock. South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell ...